title: GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study.
abstract: BACKGROUND
  Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different combinations.
  
  
  METHODS
  A Total of 44 patients identified with refractory or relapsed Hodgkin's Lymphoma were considered eligible for this study. The Patients were randomly divided into two groups of 22, one of which were treated with GDP regimen (gemcitabine, dexamethasone and cisplatin) and the other with EHSAP regimen (etoposide, methyl prednisolone, cisplatin and cytarabine) in a prospective manner. The results of each group were compared.
  
  
  RESULTS
  There were 27.3% complete response, 31.8% more than 50% response, and 40.9% no response with GDP. ESHAP results were 29.5%, 24% and 45.5%, respectively.
  
  
  CONCLUSIONS
  There is no significant difference in response rate between GDP and ESHAP regimens as salvage chemotherapy in refractory or relapsed Hodgkin's Lymphoma.
authors: Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.
authors: Mani
authors: M
authors: Ramzi
authors: Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.
authors: Aliraza
authors: A
authors: Rezvani
authors: Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.
authors: Mehdi
authors: M
authors: Dehghani
keywords: Hodgkin Lymphoma; Relapsed Hodgkin Lymphoma; Salvage Chemotherapy